title: [New medical treatments of glaucoma. New strategies?].
abstract: Several new classes of ocular hypotonia medications have recently become available. These include the topical treatments carbonic anhydrase inhibitors, the alpha-2 agonists, the prostaglandin analogues, and a fixed combination of beta-blockers and carbonic anhydrase inhibitors. With an equal or superior efficacy than beta-blockers, these new treatments must be reconsidered as first-line therapy in glaucoma. The long-term safety profile of antiglaucomatous drugs plays an important role in the new trends of medical treatment. These data, better known and detailed over time by clinical experience, are changing our habits and advancing therapeutic strategies for a more effective treatment, better suited to the individual, thus allowing the best quality of life possible.
authors.affiliation: Hôpital du Val-de-Grâce, 74, boulevard du Port-Royal, 75005 Paris.
authors.forename: J P
authors.initials: JP
authors.lastname: Renard
authors.forename: F
authors.initials: F
authors.lastname: May
authors.forename: J C
authors.initials: JC
authors.lastname: Rigal-Sastourne
authors.forename: J F
authors.initials: JF
authors.lastname: Maurin
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000068438:Brimonidine Tartrate; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D011453:Prostaglandins / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use
chemical_list: D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D011453:Prostaglandins; D011810:Quinoxalines; D000068438:Brimonidine Tartrate